Ian Somaiya

Ian original.jpg

Mr. Somaiya joined TCR² in 2018 as Chief Financial Officer. He brings more than 20 years of experience in finance and healthcare as a equity research analyst on Wall Street. Prior to joining TCR², Mr. Somaiya was Managing Director and Head of Biotechnology Research at BMO Capital Markets. During his 20-year career, Mr. Somaiya conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. Previously, he served as a Managing Director and Equity Analyst at Nomura Securities Co. Ltd., Piper Jaffray Companies and Thomas Weisel Partners Group, Inc. He launched his Wall Street career as a research analyst at Morgan Stanley and Prudential Securities, and was recognized as the "Best on the Street" by The Wall Street Journal for his coverage on biotechnology in 2006, 2007 and 2009. Mr. Somaiya received his Bachelor of Arts degree in Biology and Neuroscience from New York University.